Publication / Source: Bioanalysis 11(9)
Authors: Göpfert JC, Reiser A, Yañez VAC et al
Aim: Novel bifunctional vascular endothelial growth factor A (VEGF-A) neutralizing therapies are being developed for the treatment of retinal vascular diseases such as age-related macular degeneration and diabetic retinopathy. In developing new therapeutic drugs, only small aqueous humor sample volumes are available for analyzing several parameters. Highly sensitive detection methods must be applied in analyzing VEGF-A levels in ocular fluids in order to demonstrate VEGF-A suppression following drug administration. Experimental: A highly sensitive immunoassay for VEGF-A was developed on the single molecule array (Simoa) platform, and validated before being used for the analysis of clinical aqueous humor samples from patients treated with anti-VEGF-A therapeutics. Results: This highly sensitive immunoassay allows the detection of baseline VEGF-A levels and suppression effects after drug administration, even in sample volumes as low as 12 μl. Conclusion: The Simoa VEGF-A assay is a valuable tool for the reliable monitoring of VEGF-A suppression after intravitreal administration of anti-VEGF-A drugs.
Key words: aqueous humor, biomarker, diabetic macular edema, faricimab, immunoassay, ophthalmology, single molecule array, soluble target, VA2 Cross Mab, vascular endothelial growth factor A
Choroidal neovascular eye diseases, such as diabetic macular edema (DME), diabetic retinopathy or wet age-related macular degeneration (wAMD), are caused by abnormal leakage and neovascularization of retinal vessels and are the major causes of visual impairment worldwide [1–3]. In recent years, anti-VEGF-A drug treatments  have dramatically improved the prognosis in patients with neovascular age-related macular degeneration (nvAMD) or DME and have become standard treatment [5,6]. In clinical studies, visual acuity is usually considered to be the primary efficacy end point. In addition, aqueous humor (AH) offers further relevant parameters, with VEGF-A being one of the most notable analytes .
- Bourne RRA, Jonas JB, Bron AM et al. Prevalence and causes of vision loss in high-income countries and in eastern and central Europe in 2015: magnitude, temporal trends and projections. Br. J. Ophthalmol. 102(5), 575–585 (2018).
- Campochiaro PA. Ocular neovascularization. J. Mol. Med. (Berl.) 91(3), 311–321 (2013).
- Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 379(9827), 1728–1738 (2012).
- Krebs I, Schmetterer L, Boltz A et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br. J. Ophthalmol. 97(3), 266–271 (2013).
- Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419–1431 (2006).
- Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1432–1444 (2006).
- Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 27(4), 331–371 (2008).
- Muether PS, Droege KM, Fauser S. Vascular endothelial growth factor suppression times in patients with diabetic macular oedema treated with ranibizumab. Br. J. Ophthalmol. 98(2), 179–181 (2014).
- Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am. J. Ophthalmol. 158(3), 532–536 (2014).